公开(公告)号：US20220033462A1

公开(公告)日：2022-02-03

申请号：US17385805

申请日：2021-07-26

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： ARVIND RAJPAL ,  Shobha Chowdary Potluri ,  Laurent Poirot ,  Alexandre Juillerat ,  Thomas Charles Pertel ,  Donna Marie Stone ,  Barbra Johnson Sasu

IPC: C07K14/705 ,  C07K16/30 ,  A61K35/17 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising an extracellular domain comprising an antigen binding domain, a transmembrane domain, and, an intracellular domain wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein X1 is an amino acid X2 is an amino acid X3 is an amino acid and X4 is V or I.

公开(公告)号：US11198856B2

公开(公告)日：2021-12-14

申请号：US15069672

申请日：2016-03-14

Applicant: CELLECTIS

Inventor： Philippe Duchateau ,  Julien Valton ,  Claudia Bertonati ,  Jean-Charles Epinat ,  George H. Silva ,  Alexandre Juillerat ,  Marine Beurdeley

IPC: C12N9/16 ,  C12N15/63 ,  C07K14/195 ,  C12N9/22 ,  C07K14/47 ,  A61K38/00 ,  C12P19/34

Abstract: The present invention relates to a method for the generation of compact Transcription Activator-Like Effector Nucleases (TALENS) that can efficiently target and process double-stranded DNA. More specifically, the present invention concerns a method for the creation of TALENs that consist of a single TALE DNA binding domain fused to at least one catalytic domain such that the active entity is composed of a single polypeptide chain for simple and efficient vectorization and does not require dimerization to target a specific single double-stranded DNA target sequence of interest and process DNA nearby the DNA target sequence. The present invention also relates to compact TALENs, vectors, compositions and kits used to implement the method.

公开(公告)号：US20210268028A1

公开(公告)日：2021-09-02

申请号：US17256434

申请日：2019-06-14

Applicant: CELLECTIS

Inventor： Stéphane André DEPIL ,  Ghulam MUFTI ,  David SOURDIVE

IPC: A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  C12N5/10 ,  C12N5/0783 ,  A61K31/7076 ,  A61K31/675

Abstract: The present invention relates to compositions comprising engineered allogenic immune cells endowed with Chimeric Antigen Receptors (CAR), in particular a CAR specific for CD123 and CLL1 for treating AML patients with adverse genetic risk.

公开(公告)号：US11014989B2

公开(公告)日：2021-05-25

申请号：US15546633

申请日：2016-01-25

Applicant: Cellectis

Inventor： Julianne Smith ,  Julien Valton ,  Alexandre Juillerat ,  Philippe Duchateau ,  Barbra Johnson Sasu ,  Arvind Rajpal

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/725 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/735 ,  G01N15/10 ,  G01N15/14 ,  G01N15/00

Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward CLL1 positive cells. The engineered immune cells endowed with such CARs are particularly suited for immunotherapy for treating cancer, in particular leukemia.

公开(公告)号：US20210139870A1

公开(公告)日：2021-05-13

申请号：US16623171

申请日：2018-06-18

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU

IPC: C12N9/22 ,  A61K45/06 ,  A61K47/55 ,  A61P31/22

Abstract: The invention pertains to non-viral methods for in vivo delivery of endonuclease reagents compositions to specific tissues or cells. According to the invention, the endonuclease reagents are preferably encapsulated into micelle structures of 50 to 150 nm diameter for intravenous injection, in combination with antiviral compounds. The invention thereby provides therapeutic compositions comprising endonuclease reagents and antiviral compounds for effective elimination of HBV from liver cells and treatment of chronic hepatitis.

公开(公告)号：US20210128613A1

公开(公告)日：2021-05-06

申请号：US16629506

申请日：2018-07-20

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  Anne-Sophie GAUTRON ,  Laurent POIROT ,  Julien VALTON

IPC: A61K35/17 ,  C12N5/0783 ,  C12N15/113 ,  C07K16/28 ,  A61K39/395

Abstract: The invention pertains to the field of adoptive cell immunotherapy. It provides with engineered immune cells comprising genetic alteration into genes which are involved into immune functions downregulation, especially in response to environment signals such as nutrients depletion. Such method allows the production of more potent immune cells in the context of tumors' microenvironment.

公开(公告)号：US20210017545A1

公开(公告)日：2021-01-21

申请号：US17041359

申请日：2019-03-29

Applicant: CELLECTIS

Inventor： Alex BOYNE ,  Brian BUSSER ,  Philippe DUCHATEAU ,  Aymeric DUCLERT

IPC: C12N15/90 ,  C12N15/86 ,  C07K14/805 ,  C12N15/10 ,  C12N9/22

Abstract: The present invention relates to the field of genome engineering (gene editing). More specifically the invention provides with allele specific TALE-nucleases and methods to operate allele specific gene repair by homologous recombination in primary cells, such as hematopoietic stem cells, blood cells and hepatocytes. These reagents and methods can be used for the genetic treatment of inherited disease, such as sickle cell disease betathalassemia.

公开(公告)号：US20210002656A1

公开(公告)日：2021-01-07

申请号：US17022421

申请日：2020-09-16

Applicant: CELLECTIS

Inventor： Daniel F. Voytas ,  Feng Zhang ,  Jin Li ,  Thomas Stoddard ,  Song Luo

IPC: C12N15/82 ,  C12N9/22

Abstract: Materials and methods for creating genome-engineered plants with non-transgenic methods are provided herein.

公开(公告)号：US20210000869A9

公开(公告)日：2021-01-07

申请号：US16365588

申请日：2019-03-26

Applicant: CELLECTIS

Inventor： Roman Galetto ,  Julianne SMITH ,  Andrew SCHARENBERG ,  Cecile SCHIFFER-MANNIOUI

IPC: A61K35/17 ,  C07K14/705 ,  C12N5/0783 ,  C07K14/725 ,  C07K16/28

Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells; expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.

公开(公告)号：US10815500B2

公开(公告)日：2020-10-27

申请号：US14405283

申请日：2013-06-05

Applicant: Alexandre Juillerat ,  Philippe Duchateau ,  Cellectis

Inventor： Alexandre Juillerat ,  Philippe Duchateau

IPC: C12N15/90 ,  C12N9/22 ,  C12N15/10

Abstract: The present invention relates to Transcription Activator-Like Effector (TALE) derived proteins that allow efficient targeting and/or processing of double stranded nucleic acid sequences. The proteins of the invention are typically chimeric protein monomers composed of a core scaffold comprising Repeat Variable Dipeptide regions (RVDs) having binding specificity to a DNA target sequence, to which is fused a catalytic domain to its N-terminus. This later catalytic domain, which can be a monomer of a nuclease, is placed at this position to possibly interact with another catalytic domain fused to another TAL monomer, such that, when the monomers are binding to their respective target DNA sequences, both catalytic domains form a catalytic entity likely to process DNA in the proximity of these target sequences. This new TAL architecture makes it possible to target only one DNA strand, which is not the case, for instance, with classical TALEN architectures. The present invention also relates to vectors encoding such proteins and compositions or kits in which Transcription Activator-Like Effector (TALE) proteins of the present invention are used.